However, while treatment of FXS fibroblasts with MTX did indeed reactivate the FMR1 gene, it did not decrease promoter methylation, suggesting that its effect on FMR1 transcription was independent of local DNA demethylation [117]. The gene discussed is FMR1; the disease is fragile X syndrome.